5. Ogasawara M., Miyashita M., Yamagishi Y., Ota S. Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: A single-center phase I/II trial // Ther. Apheresis Dial. - 2021. - V. 25, No 4. - P. 415-424.
6. van Willigen W.W., Bloemendal M., Boers-Sonderen M.J., de Groot J.W.B., Koorn- straR.H.T., van der Veldt A.A.M., Haanen J.B.A.G., Boudewijns S., Schreibelt G., Gerritsen W.R., de Vries I.J.M., Bol K.F. Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination // Oncoimmunology - 2020. - V. 9, No 1. - Art. 1738814, P. 1-8.
7. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., Frohlich M.W., Schellhammer P.F. Sipuleucel-T immunotherapy for castration-resistant prostate cancer // N. Engl. J. Med. - 2010 - V. 363, No 5. - P. 411-422.
8. Балдуева ИА., Новик А.В., Моисеенко В.М., Нехаева Т.Л., Данилова А.Б., Данилов А.О., Проценко С.А., Петрова Т.Ю., Улейская Г.И., Щёкина Л.А. Клиническое исследование (II фаза) вакцины на основе аутологичных дендритных клеток с иммунологическим адъювантом у больных с меланомой кожи // Вопр. онкологии. - 2012. - Т. 58, № 2. - P. 212-221.
9. Sabado R.L., Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment // Immunotherapy. - 2010. - V. 2, No 1. - P. 37-56.
10. Wilgenhof S., Van Nuffel A.M.T., Benteyn D., Corthals J., Aerts C., Heirman C., Van RietI., Bonehill A., Thielemans K., Neyns B. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients // Ann. Oncol. - 2013. - V. 24, No 10 - P. 2686-2693.
11. Okada H., Kalinski P., Ueda R., Hoji A., Kohanbash G., Donegan T.E., Mintz A.H., Engh J.A., Bartlett D.L., Brown C.K., Zeh H., Holtzman M.P., Reinhart T.A., Whiteside T.L., Butterfield L.H., Hamilton R.L., Potter D.M., Pollack I.F., Salazar A.M., Lieberman F.S. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with a-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma // J. Clin. Oncol. - 2011. - V. 29, No 3. - P. 330-336.
12. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., Taquet S., Coquery S., Wittkowski K.M., Bhardwaj N., Pineiro L., Steinman R., Fay J. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor- derived dendritic cell vaccine // Cancer Res. - 2001. - V. 61, No 17. - P. 6451-6458.
13. Klechevsky E., Liu M., Morita R., Banchereau R., Thompson-Snipes L., Palucka A.K., Ueno H., Banchereau J. Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines // Hum. Immunol. - 2009. - V. 70, No 5. - P. 281-288.
14. Pulendran B., Banchereau J., Burkeholder S., Kraus E., Guinet E., Chalouni C., Caron D., Maliszewski C., Davoust J., Fay J., Palucka K. Flt3-ligand and granulocyte colony- stimulating factor mobilize distinct human dendritic cell subsets in vivo // J. Immunol. - 2000. - V. 165, No 1. - P. 566-572.
15. Schreibelt G., Bol K.F., Westdorp H., Wimmers F., Aarntzen E.H., Duiveman-de Boer T., van de Rakt M.W.M.M., Scharenborg N.M., de Boer A.J., Pots J.M., Olde Nordkamp MA.M., van Oorschot T.G.M., Tel J., Winkels G., Petry K., Blokx W.A.M., van Rossum M.M., Welzen M.E.B., Mus R.D.M., Croockewit S.A.J., Koornstra R.H.T., Jacobs J.F.M., Kelderman S., Blank C.U., Gerritsen W.R., Punt C.J.A., Figdor C.G., de Vries I.J.M. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells // Clin. Cancer Res. - 2016. - V. 22, No 9. - P. 2155-2166.
16. Adams S., Kozhaya L., Martiniuk F., Meng T-.C., Chiriboga L., Liebes L., Hochman T., Shuman N., Axelrod D., Speyer J., Novik Y., Tiersten A., Goldberg J.D., Formenti S.C., Bhardwaj N., Unutmaz D., Demaria S. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer // Clin. Cancer Res. - 2012. - V. 18, No 24. - P. 6748-6757.
17. Gardner A., de Mingo Pulido A., Ruffell B. Dendritic cells and their role in immunotherapy // Front. Immunol. - 2020. - V. 11. - Art. 924, P. 1-14.
18. Diener K.R., Moldenhauer L.M., Lyons A.B., Brown M.P., Hayball J.D. Human Flt-3-ligand-mobilized dendritic cells require additional activation to drive effective immune responses // Exp. Hematol. - 2008. - V. 36, No 1. - P. 51-60.
19. Chulpanova D.S., Solovyeva V.V., Kitaeva K.V., Dunham S.P., Khaiboullina S.F., Rizvanov A.A. Recombinant viruses for cancer therapy // Biomedicines. - 2018. - V. 6, No 4. - Art. 94, P. 1-14.
20. Rossowska J., Anger N., Szczygiei A., Mierzejewska J., Pajtasz-Piasecka E. Intratumoral lentivector-mediated TGF- B1 gene downregulation as a potent strategy for enhancing the antitumor effect of therapy composed of cyclophosphamide and dendritic cells // Front. Immunol. - 2017. - V. 8. - Art. 713, P. 1-15.
21. Palucka A.K., Ueno H., Connolly J., Kerneis-Norvell F., Blanck J.-P., Johnston D.A., Fay J., Banchereau J. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity // J. Immunother. - 2006. - V. 29, No 5. - P. 545-557.
22. Salcedo M., Bercovici N., Taylor R., Vereecken P., Massicard S., Duriau D., Vernel- Pauillac F., Boyer A., Baron-Bodo V., Mallard E., Bartholeyns J., Goxe B., Latour N., Leroy S., Prigent D., Martiat P., Sales F., Laporte M., Bruyns C., Romet-Lemonne J.-L., Abastado J.-P., Lehmann F., Velu T. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate // Cancer Immunol. Immunother. - 2006. - V. 55, No 7. - P. 819-829.
23. Squadrito M.L., Cianciaruso C., Hansen S.K., De Palma M. EVIR: Chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens // Nat. Methods. - 2018. - V. 15, No 3. - P. 183-186.
24. Chulpanova D.S., Kitaeva K.V., James V., Rizvanov A.A., Solovyeva V.V. Therapeutic prospects of extracellular vesicles in cancer treatment // Front. Immunol. - 2018. - V. 9. - Art. 1534, P. 1-10.
25. BlockM.S., Dietz A.B., Gustafson M.P., Kalli K.R., Erskine C.L., Youssef B., Vijay G.V., Allred J.B., Pavelko K.D., Strausbauch M.A., Lin Y., Grudem M.E., Jatoi A., Klampe C.M., Wahner-Hendrickson A.E., Weroha S.J., Glaser G.E., Kumar A., Langstraat C.L., Sol- sethM.L., Deeds M.C., Knutson K.L., Cannon M.J. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients // Nat. Commun. - 2020. - V. 11, No 1. - Art. 5173, P. 1-12.
26. Nagai K., Adachi T., Harada H., Eguchi S., Sugiyama H., Miyazaki Y. Dendritic cell- based immunotherapy pulsed with Wilms tumor 1 peptide and mucin 1 as an adjuvant therapy for pancreatic ductal adenocarcinoma after curative resection: A phase I/IIa clinical trial // Anticancer. Res. - 2020. - V. 40, No 10. - P. 5765-5776.
27. Matsui H.M., Hazama S., Nakajima M., Xu M., Matsukuma S., Tokumitsu Y., Shindo Y., Tomochika S., Yoshida S., Iida M., Suzuki N., Takeda S., Yoshino S., Ueno T., Oka M., Nagano H. Novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA for patients with hepatocellular carcinoma: A phase I/II prospective randomized controlled clinical trial // Cancer Immunol. Immunother. - 2021. - V. 70, No 4. - P. 945-957.
28. Лукашина М.И., Смирнова А., Алиев В.А., Самойленко И.В., Семенов Н.Н., Вейко В.П., Михайлова И.Н., Барсуков Ю.А., Барышников А.Ю. Дендритные вакцины в терапии колоректального рака // Вестн. РОНЦ им. Н.Н. Блохина РАМН - 2008. - Т. 19, № 3. - С. 35-42.
29. Фадеев Ф.А., Замятин А.В., Седнева-Луговец Д.В., Микеров И.А., Губаева О.В. Получение дендритных клеток для терапии онкологических заболеваний // Вестн. Урал. мед. акад. науки. - 2020. - Т. 17, №4. - С. 347-353.
30. Bulgarelli J., Tazzari M., Granato A.M., Ridolfi L., Maiocchi S., de Rosa F., Petrini M., Pancisi E., Gentili G., Vergani B., Piccinini F., Carbonaro A., Leone B.E., Foschi G., Ancarani V., Framarini M., Guidoboni M. Dendritic cell vaccination in metastatic melanoma turns “non-T cell inflamed” into “T-cell inflamed” tumors // Front. Immunol. - 2019. - V. 10. - Art. 2353, P. 1-13.
31. Taube J.M., Anders R.A., Young G.D., Xu H., Sharma R., McMiller T.L., Chen S., Klein A.P., Pardoll D.M., Topalian S.L., Chen L. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape // Sci. Transl. Med. - 2012. - V. 4, No 127. - Art. 127ra37, P. 1-22. - doi: 10.1126/scitranslmed.3003689.
32. Wilgenhof S., Corthals J., Heirman C., van Baren N., Lucas S., Kvistborg P., Thielemans K., Neyns B. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma // J. Clin. Oncol. - 2016. - V. 34, No 12. - P. 1330-1338.
33. Jansen Y., Kruse V., Corthals J., Schats K., van Dam P.-J., Seremet T., Heirman C., Brochez L., Kockx M., Thielemans K., Neyns B. A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC- MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases // Cancer Immunol. Immunother. - 2020. - V. 69, No 12. - P. 2589-2598.
34. Boudewijns S., Bloemendal M., de Haas N., Westdorp H., Bol K.F., Schreibelt G., Aarntzen E.H.J.G., Lesterhuis W.J., Gorris M.A.J., Croockewit A., van der Woude L.L., van Rossum M.M., Welzen M., de Goede A., Hato S.V., van der Graaf W.T.A., Punt C.J.A., Koornstra R.H.T., Gerritsen W.R., Figdor C.G., de Vries I.J.M. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: A prospective, randomized phase 2 trial // Cancer Immunol. Immunother. - 2020. - V. 69, No 3 - P. 477-488.
35. Петенко Н.Н., Михайлова И.Н., Чкадуа Г.З., Демидов Л.В., Барышников А.Ю. Вакцинотерапия меланомы кожи дендритными клетками после хирургического лечения // Саркомы костей, мягких тканей и опухоли кожи. - 2015. - №1. - С. 43-49.
36. Sturm D., Bender S., Jones D.T., Lichter P., Grill J., Becher O., Hawkins C., Majewski J., Jones C., Costello J.F., Iavarone A., Aldape K., Brennan C.W., Jabado N., Pfister S.M. Paediatric and adult glioblastoma: Multiform (epi)genomic culprits emerge // Nat. Rev. Cancer. - 2014. - V. 14, No 2. - P. 92-107.
37. Polyzoidis S., Ashkan K. DCVax®-L-developed by Northwest Biotherapeutics // Hum. Vaccines Immunother. - 2014. - V. 10, No 11. - P. 3139-3145.
38. Liau L.M., Ashkan K., Tran D.D., Campian J.L., Trusheim J.E., Cobbs C.S., Heth J.A., Salacz M., Taylor S., D 'Andre S.D., Iwamoto F.M., Dropcho E.J., Moshel YA., Walter K.A., Pillainayagam C.P., Aiken R., Chaudhary R., Goldlust S.A., Bota DA., Duic P., Grewal J., Elinzano H., Toms SA., Lillehei K.O., Mikkelsen T., Walbert T., Abram S.R., Brenner A.J., Brem S., Ewend M.G., Khagi S., Portnow J., Kim L.J., Loudon W.G., Thompson R.C., Avigan D.E., Fink K.L., Geoffroy F.J., Lindhorst S., Lutzky J., Sloan A.E., Schackert G., Krex D., Meisel H.-J., Wu J., Davis R.P., Duma C., Etame A.B., Mathieu D., Kesari S., Piccioni D., Westphal M., Baskin D.S., New P.Z., Lacroix M., May S.-A., Pluard T.J., Tse V., Green R.M., Villano J.L., Pearlman M., Petrecca K., Schulder M., Taylor L.P., Maida A.E., Prins R.M., Cloughesy T.F., Mulholland P., Bosch M.L. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma // J. Transl. Med. - 2018. - V. 16, No 1. - Art. 142, P. 1-9.
39. Mitsuya K., Akiyama Y., Iizuka A., Miyata H., Deguchi S., Hayashi N., Maeda C., Kondou R., Kanematsu A., Watanabe K., Ashizawa T., Abe Y., Ito I., Oishi T., Sugino T., Nakasu Y., Yamaguchi K. Alpha-type-1 polarized dendritic cell-based vaccination in newly diagnosed high-grade glioma: A phase ii clinical trial // Anticancer Res. - 2020. - V. 40, No 11. - P. 6473-6484.
40. Wang Q.-T., Nie Y., Sun S.-N., Lin T., Han R.-J., Jiang J., Li Z., Li J.-Q., Xiao Y.-P., Fan Y.-Y., Yuan X.-H., Zhang H., Zhao B.-B., Zeng M., Li S.-Y., Liao H.-X., Zhang J., He Y.-W. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients // Cancer Immunol. Immunother. - 2020. - V. 69, No 7. - P. 1375-1387.
41. Луцук Р.А., Олюшин В.Е., Тастанбеков М.М., Ростовцев Д.М., Папаян Г.В., Филатов М.В., Себелев К.И., Забродская Ю.М., Маслова Л.Н. Фотодинамическая терапия и специфическая иммунотерапия на основе аутологичных дендритных клеток в комплексном лечении пациентов с продолженным ростом злокачественных глиом // Рос. нейрохирург. журн. им. профессора А.Л. Поленова. - 2018. - Т. 10, №2. - С. 71-78.
42. Hlavackova E., Pilatova K., Cerna D., Selingerova I., Mudry P., Mazanek P., Fedorova L., Merhautova J., Jureckova L., Semerad L., Pacasova R., Flajsarova L., Souckova L., Demlova R., Sterba J., Valik D., Zdrazilova-Dubska L. Dendritic cell-based immunotherapy in advanced sarcoma and neuroblastoma pediatric patients: Anti-cancer treatment preceding monocyte harvest impairs the immunostimulatory and antigen-presenting behavior of DCs and manufacturing process outcome // Front. Oncol. - 2019. - V. 9. - Art. 1034, P. 1-15.
43. Raj S., Bui M.M., Springett G., Conley A., Lavilla-Alonso S., Zhao X., Chen D., Haysek R., Gonzalez R., Letson G.D., Finkelstein S.E., Chiappori A.A., Gabrilovitch D.I., Antonia S.J. Long-term clinical responses of neoadjuvant dendritic cell infusions and radiation in soft tissue sarcoma // Sarcoma. - 2015. - V. 2015. - Art. 614736, P. 1-8.
44. Fedorova L., Mudry P., Pilatova K., Selingerova I., Merhautova J., Rehak Z., Valik D., Hlavackova E., Cerna D., Faberova L., Mazanek P., Pavelka Z., Demlova R., Sterba J., Zdrazilova-Dubska L. Assessment of immune response following dendritic cell-based immunotherapy in pediatric patients with relapsing sarcoma // Front. Oncol. - 2019. - V. 9. - Art. 1169, P. 1-12.
45. CoxM.C., Castiello L., Mattei M., Santodonato L., D 'Agostino G., Muraro E., Martorelli D., Lapenta C., Di Napoli A., Di Landro F., Cangemi M., Pavan A., Castaldo P., Hohaus S., Donati S., Montefiore E., Berdini C., Carlei D., Monque D.M., Ruco L., Prosperi D., Tafuri A., Spadaro F., Sestili P., Spada M., Dolcetti R., Santini S.M., Rozera C., Aricd E., Capone I., Belardelli F. Clinical and antitumor immune responses in relapsed/refractory follicular lymphoma patients after intranodal injections of IFNa-dendritic cells and rituximab: A phase I clinical trial // Clin. Cancer Res. - 2019. - V. 25, No 17. - P. 5231-5241.
46. Lin Y., Atwell T., Weisbrod A., Maas M., Armstrong A., Deeds M., Bulur P., Gustafson M., Zhang Z., Cordes S., Porrata L., Markovic S., Johnston P., Micallef I., Inwards D., Colgan J., Ansell S., Gastineau D., Dietz A., Witzig T. Dendritic cell vaccine treatment for indolent B-cell non-Hodgkin lymphoma: Clinical trial in progress // Cytotherapy. - 2015. - V. 17, No 6, Suppl. - P. S17.
Figure Captions
Fig. 1. The main stages of creating a personalized antitumor vaccine based on autologous dendritic cells (DCs). Various methods for obtaining DCs from CD14+ monocytes, CD34+ hematopoietic stem cells (HSCs), and natural DCs from the patient's whole blood by apheresis are shown, as well as further maturation using a cocktail of cytokines or electroporation of mRNA of CD40L, CD70, and caTLR4. Methods for obtaining various types of tumor antigens are also summarized, such as: artificial neoantigens/peptides/mRNA of tumor antigens, lysate/inactivated tumor cells, and extracellular vesicles for activating DCs and their subsequent use as a DC vaccine. Revised from [2].
Fig. 2. The effect of dendritic vaccination. After the administration of dendritic vaccines, activated mature DCs migrate to the lymph nodes where they present tumor antigens to nawe CD8+ and CD4+ T-cells and B cells. Activated CD8+ and CD4+ T-cells and B cells migrate to the adjacent tumor tissue where the tumor cells are eliminated by activated cytotoxic CD8+ T-cells and NK cells, while CD4+ T-helpers and B cells release pro-inflammatory cytokines that enhance cytotoxic effects. Revised from [2].
References
1. Filin I.Y., Solovyeva V.V., Kitaeva K.V., Rutland C.S., Rizvanov A.A. Current trends in cancer immunotherapy. Biomedicines, 2020, vol. 8, no. 12, art. 621, pp. 1-36.
2. Filin I.Y., Kitaeva K.V., Rutland C.S., Rizvanov A.A., Solovyeva V.V. Recent advances in experimental dendritic cell vaccines for cancer. Front. Oncol., 2021, vol. 11, art. 730824, pp. 1-7.
3. Allan R.S., Waithman J., Bedoui S., Jones C.M., Villadangos J.A., Zhan Y., Lew A.M., Shortman K., Heath W.R., Carbone F.R. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity, 2006, vol. 25, no. 1, pp. 153-162.
4. Sanchez-Sanchez N., Riol-Blanco L., Rodriguez'-Fernandez J.L. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J. Immunol., 2006, vol. 176, no. 9, pp. 5153-5159.
5. Ogasawara M., Miyashita M., Yamagishi Y., Ota S. Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: A single-center phase I/II trial. Ther. Apheresis Dial., 2021, vol. 25, no. 4, pp. 415-424.
6. van Willigen W.W., Bloemendal M., Boers-Sonderen M.J., de Groot J.W.B., Koornstra R.H.T., van der Veldt A.A.M., Haanen J.B.A.G., Boudewijns S., Schreibelt G., Gerritsen W.R., de Vries I.J.M., Bol K.F. Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. Oncoimmunology, 2020, vol. 9, no. 1, art. 1738814, pp. 1-8.
7. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., Xu Y., Frohlich M.W., Schellhammer P.F. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med., 2010, vol. 363, no. 5, pp. 411-422.
8. Baldueva I.A., Novik A.V., Moiseenko V.M., Nekhaeva T.L., Danilova A.B., Danilov A.O., Protsenko S.A., Petrova T.Yu., Uleiskaya G.I., Shchekina L.A. Phase 2 clinical trial of the autologous dendritic cell vaccine with an immunologic adjuvant in patients with cutaneous melanoma. Vopr. Onkol., 2012, vol. 58, no. 2, pp. 212-221. (In Russian)
9. Sabado R.L., Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy, 2010, vol. 2, no. 1, pp. 37-56.
10. Wilgenhof S., Van Nuffel A.M.T., Benteyn D., Corthals J., Aerts C., Heirman C., Van Riet I., Bonehill A., Thielemans K., Neyns B. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann. Oncol., 2013, vol. 24, no. 10, pp. 2686-2693.
11. Okada H., Kalinski P., Ueda R., Hoji A., Kohanbash G., Donegan T.E., Mintz A.H., Engh J.A., Bartlett D.L., Brown C.K., Zeh H., Holtzman M.P., Reinhart T.A., Whiteside T.L., Butterfield L.H., Hamilton R.L., Potter D.M., Pollack I.F., Salazar A.M., Lieberman F.S. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with a-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol., 2011, vol. 29, no. 3, pp. 330-336.
12. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., Taquet S., Coquery S., Wittkowski K.M., Bhardwaj N., Pineiro L., Steinman R., Fay J. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res., 2001, vol. 61, no. 17, pp. 6451-6458.
13. Klechevsky E., Liu M., Morita R., Banchereau R., Thompson-Snipes L., Palucka A.K., Ueno H., Banchereau J. Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum. Immunol., 2009, vol. 70, no. 5, pp. 281-288.
14. Pulendran B., Banchereau J., Burkeholder S., Kraus E., Guinet E., Chalouni C., Caron D., Maliszewski C., Davoust J., Fay J., Palucka K. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol., 2000, vol. 165, no. 1, pp. 566-572.
15. Schreibelt G., Bol K.F., Westdorp H., Wimmers F., Aamtzen E.H., Duiveman-de Boer T., van de Rakt M.W.M.M., Scharenborg N.M., de Boer A.J., Pots J.M., Olde Nordkamp M.A.M., van Oorschot T.G.M., Tel J., Winkels G., Petry K., Blokx W.A.M., van Rossum M.M., Welzen M.E.B., Mus R.D.M., Croockewit S.A.J., Koornstra R.H.T., Jacobs J.F.M., Kelderman S., Blank C.U., Ger- ritsen W.R., Punt C.J.A., Figdor C.G., de Vries I.J.M. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin. Cancer Res., 2016, vol. 22, no. 9, pp. 2155-2166.
16. Adams S., Kozhaya L., Martiniuk F., Meng T.-C., Chiriboga L., Liebes L., Hochman T., Shuman N., Axelrod D., Speyer J., Novik Y., Tiersten A., Goldberg J.D., Formenti S.C., Bhardwaj N., Unutmaz D., Demaria S. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin. Cancer Res., 2012, vol. 18, no. 24, pp. 6748-6757.
17. Gardner A., de Mingo Pulido A., Ruffell B. Dendritic cells and their role in immunotherapy. Front. Immunol., 2020, vol. 11, art. 924, pp. 1-14.